TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07913360: A Multicenter, Open-label, Randomized Controlled Phase III Study Evaluating the Efficacy and Safety/Tolerability of GFH375 in Combination With Cetuximab Versus Investigator's Choice of Treatment in Patients With KRAS G12

Sponsor: Genfleet Therapeutics (Shanghai) Inc. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 368 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT07913360 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07913360 Rescue Dossier →